Home > Healthcare > Medical Devices > Diagnostic Devices > tuberculosis diagnostics test market
Get a free sample of Tuberculosis Diagnostics Test Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Tuberculosis Diagnostics Test Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The tuberculosis diagnostics test industry is consolidated, with key players including Abbott Laboratories, Becton, Dickinson and Company (BD), F. Hoffmann-La Roche Ltd, Qiagen N.V., and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares.
For instance, in January 2023, QIAGEN announced an exclusive strategic collaboration with Helix, a population genomics leader based in California, aimed at advancing companion diagnostics for hereditary diseases. In this partnership, QIAGEN leveraged its biopharma relationships, Next-Generation Sequencing (NGS) capabilities, and global regulatory expertise through the Helix Laboratory Platform. The collaboration marked a significant step forward, enhancing critical access to genomic testing for patients and healthcare providers combating life-threatening conditions. Additionally, it positioned QIAGEN with a competitive edge in the diagnostic market.
Some of the eminent market participants operating in the tuberculosis diagnostics test industry include:
U.S. tuberculosis diagnostics test market accounted for USD 846 million in 2023 and is predicted to witness substantial growth through 2032, favored by the advanced healthcare infrastructure, a robust R&D landscape, and a high prevalence of TB in the region.
The pathological laboratories segment garnered USD 1.20 billion revenue in 2023, attributed to the crucial role in conducting sophisticated diagnostic tests, including Nucleic Acid Amplification Tests (NAATs), molecular assays, and other pathological screening.
The global tuberculosis diagnostics test industry was valued at USD 2.3 billion in 2023 and is estimated to reach USD 3.7 billion by 2032, owing to the rising prevalence of TB.
Abbott Laboratories, Thermo Fisher Scientific Inc., Becton, Dickinson and Company (BD), Siemens Healthineers AG., bioM